Fiche du document
14 décembre 2022
- doi: 10.1038/s41467-022-35378-z
- issn: 2041-1723
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41467-022-35378-z
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36517508
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2041-1723
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C3372ED961AB3
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Mots-clés
Humans; Cell Line, Tumor; Synthetic Lethal Mutations; Neoplasms/drug therapy; Neoplasms/geneticsSujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
S. Srivatsa et al., « Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens. », Serveur académique Lausannois, ID : 10.1038/s41467-022-35378-z
Métriques
Partage / Export
Résumé
The development of cancer therapies is limited by the availability of suitable drug targets. Potential candidate drug targets can be identified based on the concept of synthetic lethality (SL), which refers to pairs of genes for which an aberration in either gene alone is non-lethal, but co-occurrence of the aberrations is lethal to the cell. Here, we present SLIdR (Synthetic Lethal Identification in R), a statistical framework for identifying SL pairs from large-scale perturbation screens. SLIdR successfully predicts SL pairs even with small sample sizes while minimizing the number of false positive targets. We apply SLIdR to Project DRIVE data and find both established and potential pan-cancer and cancer type-specific SL pairs consistent with findings from literature and drug response screening data. We experimentally validate two predicted SL interactions (ARID1A-TEAD1 and AXIN1-URI1) in hepatocellular carcinoma, thus corroborating the ability of SLIdR to identify potential drug targets.
